ZAMBON, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.155
EU - Europa 1.204
AS - Asia 788
SA - Sud America 20
OC - Oceania 14
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.140
IT - Italia 405
CN - Cina 349
SG - Singapore 348
DE - Germania 177
FI - Finlandia 165
UA - Ucraina 144
FR - Francia 85
GB - Regno Unito 81
SE - Svezia 75
VN - Vietnam 34
IN - India 20
IE - Irlanda 18
NL - Olanda 16
AU - Australia 12
CA - Canada 12
RU - Federazione Russa 7
HK - Hong Kong 6
KR - Corea 6
BG - Bulgaria 5
CO - Colombia 5
GR - Grecia 5
RO - Romania 5
AR - Argentina 4
BE - Belgio 4
BR - Brasile 4
JP - Giappone 4
LT - Lituania 4
EC - Ecuador 3
ES - Italia 3
ID - Indonesia 3
MX - Messico 3
MY - Malesia 3
TR - Turchia 3
BD - Bangladesh 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
KE - Kenya 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PE - Perù 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
DK - Danimarca 1
HU - Ungheria 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
PY - Paraguay 1
Totale 9.190
Salva come PNG Salva come JPEG
Città #
Fairfield 1.071
Woodbridge 780
Houston 572
Jacksonville 542
Ann Arbor 496
Ashburn 466
Cambridge 428
Seattle 426
Chandler 391
Wilmington 390
Singapore 274
Princeton 216
Boardman 183
San Diego 149
Santa Clara 98
Beijing 96
Des Moines 81
Medford 81
Roxbury 74
Padova 73
Helsinki 65
Nanjing 43
Dong Ket 34
Guangzhou 31
Shenyang 24
Milan 23
Hebei 22
Rome 21
Nanchang 19
Jiaxing 17
Norwalk 17
London 16
Catania 12
Dublin 11
Changsha 10
Redwood City 10
Tianjin 10
Munich 7
Nürnberg 7
Florence 6
Jinan 6
New York 6
Ogden 6
Paris 6
Selvazzano Dentro 6
Tappahannock 6
Borås 5
Frankfurt am Main 5
Hong Kong 5
Kharkiv 5
Toronto 5
Verona 5
Arzignano 4
Brussels 4
Chioggia 4
Chiswick 4
Envigado 4
Genoa 4
Hefei 4
Islington 4
Montesilvano Marina 4
Mykolayiv 4
Phoenix 4
Pune 4
Turin 4
Athens 3
Bolzano 3
Brisbane 3
Delhi 3
Detroit 3
Hounslow 3
Isola del Giglio 3
Istanbul 3
Kilburn 3
Leawood 3
Melbourne 3
Naples 3
New Haven 3
Palermo 3
Perth 3
Procida 3
Quito 3
Rockville 3
Segrate 3
Torre Del Greco 3
Vicenza 3
Zhengzhou 3
Altopascio 2
Amman 2
Baltimore 2
Beiuș 2
Birmingham 2
Bologna 2
Bondeno 2
Breda 2
Briosco 2
Buenos Aires 2
Canosa di Puglia 2
Caorso 2
Chicago 2
Totale 7.502
Salva come PNG Salva come JPEG
Nome #
Mappatura Genetica dell' Ipercolesterolemia Familiare: dati preliminari dell'esperienza padovana 224
Atorvastatin Reduces Macrophage Accumulation in Atherosclerotic Plaques. A Comparison of a Nonstatin-Based Regimen in Patients Undergoing Carotid Endarterectomy. 143
Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition. 141
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy 139
SGLT2 Inhibitors and the Diabetic Kidney 138
Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells 134
Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: impact of plaque composition and lipoprotein phenotype. 133
Dyslipidemia of the Plurimetabolic Syndrome and risk of cerebrovascular events 131
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia 129
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i) 126
Accuracy of diagnostic criteria for sporadic Creutzfeldt-Jakob disease among rapidly progressive dementia 125
Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C 123
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key? 121
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement 118
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase mediated changes in LDL density 116
The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity 114
Pro-atherogenic postprandial profile: Meal induced changes of lipoprotein sub-fractions and inflammation markers in obese boys 109
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity 109
A common hepatic lipase gene promoter variant determines clinical response to intensive lipid lowering treatment 106
LIPOPROTEIN COMPOSITIONAL ABNORMALITIES IN TYPE 1 (INSULIN-DEPENDENT) DIABETIC PATIENTS 105
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential 104
Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins 104
Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol 103
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease 102
γ-Hydroxybutyric acid-induced psychosis and seizures. 98
PLASMA TRIGLYCERIDE AND LDL HETEROGENEITY IN FAMILIAL COMBINED HYPERLIPIDEMIA 97
Association between the -514 C to T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis 94
Reducing vascular risk in the diabetic patient: implications from the FIELD study 93
A common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment 92
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 91
Genetic Diagnosis of Familial Hypercholesterolaemia: preliminary data from the University of Padua outpatient lipid clinic. 91
Lipoprotein abnormalities in well-treated type II diabetic patients. 90
Residual cardiovascular risk in secondary prevention. 89
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 89
Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. 89
Premature coronary artery disease and apolipoprotein B and apolipoprotein A-I 87
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy 86
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia 86
Non-pharmacological control of plasma cholesterol levels. 85
Type 2 diabetes patients: profiles, treatment and daily practice 84
DIMERIC LIPOPROTEIN LIPASE ACTIVITY IS BOUND TO TRIGLYCERIDE-RICH LIPOPROTEINS IN POSTHEPARIN PLASMA 82
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. 81
The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study 76
Effect of Ritonavir on lipids and post-heparin lipase activities in normal subjects 76
FAMILIAL COMBINED HYPERLIPIDEMIA AND GENETIC RISK FOR ATHEROSCLEROSIS 76
Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia. 74
The role of fenofibrate in clinical practice. 73
The Plurimetabolic Syndrome: qualitative lipoprotein abnormalities and atherosclerosis 73
Changes in LDL density across the menopausal transition 72
The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. 72
Residual macrovascular risk in 2013: what have we learned? 71
Liporpotein distribution and composition during simvastatin treatment in heterozygous FH patients 70
COMPOSITIONAL DIFFERENCES OF LOW DENSITY LIPOPROTEIN (LDL) PARTICLES IN NORMAL SUBJECTS WITH LDL PHENOTYPE A AND LDL PHENOTYPE B 69
Le basi razionali della terapia delle ipercolesterolemie 69
Statin treatment and carotid plaque composition: A review of clinical studies 68
Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. 68
DRUG TREATMENT OF HYPERLIPIDEMIA IN THE ELDERLY: A MULTICENTER DOUBLE BLIND TRIAL WITH PRAVASTATIN AND BEZAFIBRATE 67
EFFECT OF HEPATIC LIPASE ON LDL IN NORMAL MALES AND THOSE WITH CORONARY ARTERY DISEASE 66
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. 66
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes 66
PARAOXONASE GENOTYPES, LIPOPROTEIN LIPASE ACTIVITY AND HIGH DENSITY LIPOPROTEINS 65
Le linee guida nella prevenzione della cardiopatia ischemica 63
Leptin is associated with the size of the apolipoprotein(a) particle in African tribal populations living on fish or vegetarian diet 62
Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia 62
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile 62
A common polymorphism of the hepatic lipase gene as a determinant of LDL particle density and prevalence of macrophages in carotid plaque of patients with cerebrovascular disease 60
Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population the Italian longitudinal study on aging 60
Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato 60
La lipasi epatica influenza il metabolismo lipoproteico nell'uomo con meccanismo indipendente dalla sua attività enzimatica 59
Serum lipoprotein profile and APOE genotype in Alzheimer's disease 59
Obesità e dislipidemia 57
A common polymorphism in the promoter of the hepatic lipase gene significanlty affect hepatic lipase activity, LDL density and HDL2 cholesterol 56
LIPOPROTEIN ABNORMALITIES IN HYPERTRIGLYCERIDEMIC PATIENTS ON LONG-TERM HAEMODIALYSIS 56
PREVENTION OF RAISED LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN A PATIENT WITH HYPERCHOLESTEROLEMIA AND LIPOPROTEIN LIPASE DEFICIENCY 56
THE LIPOPROTEIN METABOLISM IN THE PLURIMETABOLIC SYNDROME 56
TRATTAMENTO DELL'OBESITA' 55
Hepatic lipase as a focal point for coronary artery disease regression with lipid lowering therapy 55
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy 55
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. 55
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. 54
LDL density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease 54
Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy 54
Plasma phospholipid fatty acid composition, lipid oxidation and inflammatory parameters in a population of fishermen 54
Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial 53
Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice 53
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators. Clinical and Experimental Evidence. 52
LIPOPROTEIN SUB-FRACTION LEVELS AND COMPOSITION IN OBESE SUBJECTS BEFORE AND AFTER GASTROPLASTY 52
In vivo evidence for a role hepatic lipase in human apo B containing lipoprotein metabolism, independent of its lipolytic activity 51
Relevance of the -514 C to T hepatic lipase gene promoter variant in predicting individual CAD response to intensive lipid-lowering therapy 51
C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? 51
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. 50
FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA 50
Reducing cholesterol levels to decrease cardiovascular events: The role of new proprotein convertase subtilisin/kexin type 9 inhibitors 50
OMEGA-3 POLYUNSATURATED FATTY ACIDS SUPPLEMENTATION AND CARDIOVASCULAR OUTCOMES: DO FORMULATION, DOSAGE, AND BASELINE CARDIOVASCULAR RISK MATTER? AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 50
Lipoprotein classes and coronary disease regression 49
Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts 49
Reported muscle symptoms during statin treatment among Italian dyslipidemic patients in the real-life setting: The Prosisa Study 49
Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in madly obese women 48
FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA 48
ANALYSIS OF TECHNIQUES TO OBTAIN PLASMA FOR MEASUREMENTS OF LEVELS OF FREE FATTY ACIDS 47
Totale 8.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.719
article - articoli 31.332
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.085
Totale 69.136
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.117 0 0 0 0 147 142 132 180 145 137 148 86
2020/20211.452 81 151 80 122 36 98 44 156 211 199 187 87
2021/20221.664 49 229 208 129 54 96 76 169 43 56 175 380
2022/20231.055 272 72 7 97 155 141 6 81 118 13 68 25
2023/2024623 26 68 62 66 37 40 49 24 38 20 96 97
2024/2025850 14 205 156 123 352 0 0 0 0 0 0 0
Totale 9.323